- Home
- TLSI vs FNGR Comparison
TLSI vs FNGR Comparison
Compare TLSI & FNGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- FNGR
- Stock Information
- Founded
- TLSI 2010
- FNGR 2016
- Country
- TLSI United States
- FNGR Singapore
- Employees
- TLSI N/A
- FNGR N/A
- Industry
- TLSI Medical Specialities
- FNGR Computer Software: Prepackaged Software
- Sector
- TLSI Health Care
- FNGR Technology
- Exchange
- TLSI Nasdaq
- FNGR Nasdaq
- Market Cap
- TLSI 204.0M
- FNGR 118.0M
- IPO Year
- TLSI N/A
- FNGR N/A
- Fundamental
- Price
- TLSI $5.07
- FNGR $2.08
- Analyst Decision
- TLSI Strong Buy
- FNGR
- Analyst Count
- TLSI 5
- FNGR 0
- Target Price
- TLSI $10.90
- FNGR N/A
- AVG Volume (30 Days)
- TLSI 154.9K
- FNGR 303.4K
- Earning Date
- TLSI 08-13-2025
- FNGR 07-07-2025
- Dividend Yield
- TLSI N/A
- FNGR N/A
- EPS Growth
- TLSI N/A
- FNGR N/A
- EPS
- TLSI N/A
- FNGR N/A
- Revenue
- TLSI $32,141,000.00
- FNGR $35,607,614.00
- Revenue This Year
- TLSI $55.52
- FNGR N/A
- Revenue Next Year
- TLSI $54.76
- FNGR N/A
- P/E Ratio
- TLSI N/A
- FNGR N/A
- Revenue Growth
- TLSI 46.20
- FNGR N/A
- 52 Week Low
- TLSI $3.50
- FNGR $1.03
- 52 Week High
- TLSI $6.04
- FNGR $5.20
- Technical
- Relative Strength Index (RSI)
- TLSI 45.72
- FNGR 39.44
- Support Level
- TLSI $4.81
- FNGR $1.94
- Resistance Level
- TLSI $5.63
- FNGR $2.13
- Average True Range (ATR)
- TLSI 0.35
- FNGR 0.14
- MACD
- TLSI -0.03
- FNGR 0.01
- Stochastic Oscillator
- TLSI 30.95
- FNGR 39.02
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.